GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Cash-to-Debt

Cybin (CYBN) Cash-to-Debt : 106.48 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cybin's cash to debt ratio for the quarter that ended in Dec. 2023 was 106.48.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cybin could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Cybin's Cash-to-Debt or its related term are showing as below:

CYBN' s Cash-to-Debt Range Over the Past 10 Years
Min: 106.56   Med: No Debt   Max: No Debt
Current: 106.56

During the past 4 years, Cybin's highest Cash to Debt Ratio was No Debt. The lowest was 106.56. And the median was No Debt.

CYBN's Cash-to-Debt is ranked better than
79.34% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs CYBN: 106.56

Cybin Cash-to-Debt Historical Data

The historical data trend for Cybin's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cybin Cash-to-Debt Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Cash-to-Debt
No Debt No Debt No Debt No Debt

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt 106.48

Competitive Comparison of Cybin's Cash-to-Debt

For the Biotechnology subindustry, Cybin's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cybin's Cash-to-Debt falls into.


Cybin Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cybin's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cybin had no debt (1).

Cybin's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=29.069 / (0.242 + 0.031)
=106.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cybin  (AMEX:CYBN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cybin Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cybin's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin (CYBN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Cash-to-Debt
Comparable Companies
TSX:FRX TSX:SVA TSX:ONC NEOE:MMED TSX:EPRX XCNQ:DTC TSXV:NGEN TSX:BCT XCNQ:MSET TSXV:ARCH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
R7E1:Germany R7E1:Germany CYBN:Canada
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Website
https://www.cybin.com
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.